Bandaríkin - enska - NLM (National Library of Medicine)

a-s medication solutions - maraviroc (unii: md6p741w8a) (maraviroc - unii:md6p741w8a) - maraviroc 300 mg - selzentry is indicated in combination with other antiretroviral agents for the treatment of only ccr5-tropic human immunodeficiency virus type 1 (hiv-1) infection in patients 2 years of age and older weighing at least 10 kg. limitations of use: selzentry is contraindicated in patients with severe renal impairment or esrd (crcl less than 30 ml per minute) who are concomitantly taking potent cyp3a inhibitors or inducers [see warnings and precautions (5.3)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to selzentry during pregnancy. physicians are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary limited data on the use of selzentry during pregnancy from the apr and case reports are not sufficient to inform a drug-associated risk of birth defects and miscarriage. in animal reproduction studies, no evidence of adverse developmental outcomes was observed with maraviroc. durin

Írland - enska - HPRA (Health Products Regulatory Authority)

novartis ireland limited - ondansetron - oral lyophilisate - 8 milligram(s) - serotonin (5ht3) antagonists; ondansetron

Írland - enska - HPRA (Health Products Regulatory Authority)

novartis ireland limited - ondansetron - oral lyophilisate - 4 milligram(s) - serotonin (5ht3) antagonists; ondansetron

Bandaríkin - enska - NLM (National Library of Medicine)

assertio therapeutics, inc. - diclofenac potassium (unii: l4d5ua6cb4) (diclofenac - unii:144o8ql0l1) -       cambia (diclofenac potassium for oral solution) is indicated for the acute treatment of migraine attacks with or without aura in adults (18 years of age or older). - cambia is not indicated for the prophylactic therapy of migraine. - the safety and effectiveness of cambia have not been established for cluster headache, which is present in an older, predominantly male population. - cambia is contraindicated in patients with known hypersensitivity (e.g., anaphylactoid reactions and serious skin reactions) to diclofenac [see warnings and precautions (5.7, 5.8) ]. - cambia is contraindicated in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic-like reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.12) ]. - cambia is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (

Bandaríkin - enska - NLM (National Library of Medicine)

atlantic biologicals corps - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - the use of metoclopramide oral solution is recommended for adults only. therapy should not exceed 12 weeks in duration. metoclopramide oral solution usp is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. metoclopramide is indicated for the relief of

Bandaríkin - enska - NLM (National Library of Medicine)

atlantic biologicals corps - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - the use of metoclopramide oral solution is recommended for adults only. therapy should not exceed 12 weeks in duration. metoclopramide oral solution usp is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. metoclopramide is indicated for the relief of

Bandaríkin - enska - NLM (National Library of Medicine)

remedyrepack inc. - carbamazepine (unii: 33cm23913m) (carbamazepine - unii:33cm23913m) - tegretol is indicated for use as an anticonvulsant drug. evidence supporting efficacy of tegretol as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: - partial seizures with complex symptomatology (psychomotor, temporal lobe). patients with these seizures appear to show greater improvement than those with other types. - generalized tonic-clonic seizures (grand mal). - mixed seizure patterns which include the above, or other partial or generalized seizures. absence seizures (petit mal) do not appear to be controlled by tegretol (see precautions, general). tegretol is indicated in the treatment of the pain associated with true trigeminal neuralgia. beneficial results have also been reported in glossopharyngeal neuralgia. this drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. tegretol should not be used in patients with a history of previous bone marrow depression, hypersensitivity to the drug,

Bandaríkin - enska - NLM (National Library of Medicine)

ultradent products, inc. - benzocaine (unii: u3rsy48jw5) (benzocaine - unii:u3rsy48jw5) - oral anesthetic for the temporary relief of occasional minor irritation and pain, associated with: - minor dental procedures - sore mouth and throat - minor injury of the gums - canker sores - minor irritation of the mouth or gums caused by dentures or orthodontic appliances. - if tamper-evident seal is broken. store at room temperature.

Bandaríkin - enska - NLM (National Library of Medicine)

ultradent products, inc. - benzocaine (unii: u3rsy48jw5) (benzocaine - unii:u3rsy48jw5) - oral anesthetic for the temporary relief of occasional minor irritation and pain, associated with: - minor dental procedures - sore mouth and throat - minor injury of the gums - canker sores - minor irritation of the mouth or gums caused by dentures or orthodontic appliances. - if tamper-evident seal is broken. store at room temperature.

Malasía - enska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - carbocisteine(methyl); promethazine hydrochloride -